Our anti-GFAP in Alzheimer’s disease study

March 2023 (The Chinese University of Hong Kong, Shatin, N.T., Hong Kong SAR, People’s Republic of China).

Patchouli alcohol: a promising natural treatment of Alzheimer’s disease?

Patchouli alcohol attenuates the cognitive deficits in a transgenic mouse model of Alzheimer’s disease. Featured in this study is our TripleA Polyclonal anti-GFAP (HPA056030). 

Alzheimer’s disease (AD), a chronic neurodegenerative disease characterized by progressive cognitive dysfunctions and behavioral impairments, accounts for approximately 60–70% of all dementia cases. Clinically, AD causes memory loss, mood changes, social withdrawal, and declines in thinking and behavioral skills. No cure for AD is available at present, and current therapeutics in the clinic can only provide AD patients with temporary symptomatic relief.

Patchouli alcohol (PA), the major chemical component of patchouli oil, exhibits multiple pharmacological properties, including neuroprotective effects.

This study by Xu et al. (2023) aimed to investigate the therapeutic effects of PA in Alzheimer’s disease (AD) using the TgCRND8 transgenic AD mouse model.

The results demonstrated that PA could ameliorate the cognitive deficits in TgCRND8 mice by suppressing amyloid-beta plaque deposition, hyperphosphorylation of tau protein, neuroinflammation, and gut dysbiosis.

Read more: https://lnkd.in/dXTgdrCp

Xu, QQ., Su, ZR., Yang, W. et al. Patchouli alcohol attenuates the cognitive deficits in a transgenic mouse model of Alzheimer’s disease via modulating neuropathology and gut microbiota through suppressing C/EBPβ/AEP pathway. J Neuroinflammation 20, 19 (2023).


👉 Featured in this study is our anti-GFAP (HPA056030) TripleA Polyclonal.



🌎 Our antibodies are used worldwide. Here are some latest publications 🌏